0QLQ Stock Chart & Stats
CHF390.20
CHF1.08(0.28%)
At close: 4:00 PM EDT
CHF390.20
CHF1.08(0.28%)
Day’s Range― - ―
52-Week RangeCHF263.50 - CHF418.00
Previous CloseN/A
Volume1.48K
Average Volume (3M)3.13K
Market Cap
CHF5.06B
Enterprise ValueCHF4.81B
Total Cash (Recent Filing)CHF28.56M
Total Debt (Recent Filing)CHF260.77M
Price to Earnings (P/E)23.6
Beta0.78
Next Earnings
Nov 11, 2026EPS Estimate
5.25Next Dividend Ex-DateN/A
Dividend Yield1.14%
Share Statistics
EPS (TTM)16.31
Shares Outstanding13,149,739
10 Day Avg. Volume2,034
30 Day Avg. Volume3,135
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.02
Price to Sales (P/S)5.14
P/FCF Ratio-229.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF373.67Price Target Upside-4.24% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)13.21
Revenue Forecast (FY)CHF708.49M
Bulls Say, Bears Say
Bulls Say
Large, Diversified Delivery Systems PipelineA deep pipeline (≈260 projects) with a ~70% hit rate and >130 clients creates durable revenue optionality: successful conversions into commercial production drive recurring device and consumable sales over 2–5 years, reducing concentration risk and smoothing future revenue streams.
High Margins And Improving ProfitabilityDelivery Systems' sustained 33% EBIT margin and marked improvement in net income demonstrate strong unit economics. The B2B device model benefits from scale and repeat production contracts, supporting margin sustainability as projects move from development to volume manufacturing.
Capital Efficiency And Resilient Balance SheetRobust operating cash generation (>CHF300m), rising equity (CHF748m in 2026 vs CHF395m in 2021), net debt/EBITDA ~0.8 and ROCE ~20% show capital-efficient growth. This balance supports continued capex, customer co‑financing and strategic expansion without excessive leverage.
Bears Say
Persistent Negative Free Cash FlowDespite strong operating cash, FCF has remained negative across multiple years, driven by heavy investment and working-capital swings. Persistent negative FCF constrains liquidity, may require external funding or slower buybacks, and reduces financial flexibility if the trend continues.
Recent Group Revenue DeclineA 2026 group top-line contraction introduces structural growth risk: lower revenue can pressure capacity utilization, extend payback on recent capex and make achievement of mid‑term sales targets dependent on converting pipeline projects and offsetting phased revenue changes.
Near-term Headwinds From Transitions & Ramp-up CostsMajor footprint projects and site transitions create ramp‑up inefficiencies and stranded costs that compress margins until new capacity reaches steady utilization. Combined with site moves this can depress near‑term profitability and delay realization of expected capacity-driven revenue gains.
0QLQ FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest share price was CHF263.50 and its highest was CHF418.00 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF5.06B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is Nov 11, 2026 which is in 96 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on May 20, 2026. The company reported CHF6.11 earnings per share for the quarter, beating the consensus estimate of CHF6 by CHF0.11.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Overvalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF4.4 which represents an annual dividend yield of 1.14%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 5.25.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,149,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF6.11 in its last earnings report, beating expectations of CHF6. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in GB:0QLQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
0QLQ Stock 12 Month Forecast
Average Price Target
CHF373.67
▼(-4.24% Downside)